Elanco Animal Health Financials - Benzinga

Elanco Animal Health Inc

ELANNYSE

Trade with Public

Trade with Public

$24.07

0.150.63%

Últ. Act.: Sep 1, 1:07 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Elanco Animal Health Financials

Elanco Animal Health (ELAN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products

Elanco beat second-quarter estimates, raised 2026 guidance and cited strong Pet Health demand, Zenrelia growth and expanding margins.

Vandana Singh

PRO
Elanco Animal Health Sees Q3 Adj EPS $0.19-$0.22 vs $0.20 Est; Sees Sales $1.195B-$1.220B vs $1.192B Est

Elanco Animal Health (NYSE:ELAN) is looking for Q3 Adj EPS of $0.19-$0.22 vs $0.20 analyst estimate. sees sales of $1.195 billion-$1.220 billion vs $1.192 billion analyst estimate.

Benzinga Newsdesk

PRO
Elanco Animal Health Raises FY2026 Adj EPS Guidance from $1.03-$1.09 to $1.10-$1.16 vs $1.09 Est; Raises FY2026 Sales Guidance from $5.010B-$5.085B to $5.090B-$5.140B vs $5.062B Est

Elanco Animal Health (NYSE:ELAN) raises FY2026 Adj EPS guidance from $1.03-$1.09 to $1.10-$1.16 vs $1.09 analyst estimate. Raises FY2026 sales outlook from $5.010 billion-$5.085 billion to $5.090 billion-$5.140 billion

Benzinga Newsdesk

PRO
Elanco Animal Health Q2 Adj. EPS $0.34 Beats $0.27 Estimate, Sales $1.368B Beat $1.313B Estimate

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum

Elanco Animal Health rallies after emergency use approvals and Q1 earnings beat, with higher guidance.

Vandana Singh

© 2026 Benzinga | All Rights Reserved